Back to Search Start Over

Refractory Hypothyroidism: Unraveling the Complexities of Diagnosis and Management.

Authors :
Quiroz-Aldave JE
Concepción-Zavaleta MJ
Durand-Vásquez MDC
Concepción-Urteaga LA
Gamarra-Osorio ER
Suárez-Rojas J
Rafael-Robles LDP
Paz-Ibarra J
Román-González A
Source :
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists [Endocr Pract] 2023 Dec; Vol. 29 (12), pp. 1007-1016. Date of Electronic Publication: 2023 Sep 13.
Publication Year :
2023

Abstract

Introduction: Refractory hypothyroidism (RH) represents a challenge in the diagnosis and treatment within the field of thyroidology. It is defined as the inability to achieve disease control despite using levothyroxine (LT4) doses of 1.9 μg/kg/d or higher.<br />Methods: A comprehensive review, encompassing 103 articles, was conducted using the Scielo, Scopus, and EMBASE databases, providing an approach to evaluation and diagnosis of this condition.<br />Results: LT4 disintegrates and dissolves within an acidic gastric environment before being absorbed in the jejunum and ileum. It then extensively binds to serum transporter proteins and undergoes deiodination to yield tri-iodothyronine, the biologically active hormone. There are various nonpathological causes of RH, such as noncompliance with treatment, changes in the brand of LT4, food and drug interferences, as well as pregnancy. Pathological causes include lactose intolerance, Helicobacter pylori infection, giardiasis, among others. The diagnosis of RH involves conducting a thorough medical history and requesting relevant laboratory tests to rule out causes of treatment resistance. The LT4 absorption test allows for the identification of cases of malabsorption. The treatment of RH involves identifying and addressing the underlying causes of noncompliance or malabsorption. In cases of pseudomalabsorption, supervised and weekly administration of LT4 may be considered.<br />Discussion: Early recognition of RH and correction of its underlying cause are of utmost importance, as this avoids the use of excessive doses of LT4 and prevents cardiovascular and bone complications associated with this condition.<br />Competing Interests: Disclosure The authors have no multiplicity of interest to disclose.<br /> (Copyright © 2023 AACE. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1530-891X
Volume :
29
Issue :
12
Database :
MEDLINE
Journal :
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Publication Type :
Academic Journal
Accession number :
37714332
Full Text :
https://doi.org/10.1016/j.eprac.2023.09.003